Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) announced a late-breaking poster acceptance for its Phase 2a TILS-025 study of intranasal foralumab in Multiple System Atrophy (MSA) at the 7th World Parkinson Congress, May 24-27, 2026 in Phoenix.

The poster describes the open-label trial (NCT06868628) enrolling up to 10 MSA patients to assess microglial activation by TSPO PET and clinical scores over six months.

News Market Reaction – TLSA

+12.17%

12 alerts

+12.17% Session close to close

+8.3% Peak in 1 hr 33 min

$165.95M Market Cap

1.3x Rel. Volume

In the Apr 14 session, TLSA gained 12.17%, reflecting a significant positive market reaction. Argus tracked a peak move of +8.3% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +12.2% in the session following this news. A strong positive reaction aligns with T...

Analysis

The stock surged +12.2% in the session following this news. A strong positive reaction aligns with Tiziana’s pattern of favorable responses to neuroinflammation updates and trial-related milestones, as seen after prior biomarker and financing news with moves near 15.86%. Investors might also have weighed earlier dilution events and clinical execution risks. Sustainability often depended on continued data delivery from Phase 2 programs in na‑SPMS and MSA and visibility on future funding needs.

Key Figures

Congress date: May 24–27, 2026 Planned enrollment: Up to 10 subjects Patient age range: 30–85 years +4 more

7 metrics

Congress date May 24–27, 2026 7th World Parkinson Congress presentation window

Planned enrollment Up to 10 subjects Phase 2a TILS-025 MSA trial size

Patient age range 30–85 years Eligibility criteria for TILS-025 MSA trial

Foralumab dose 50 μg per dose Intranasal foralumab dosing in TILS-025

Treatment duration 6 months Intranasal foralumab treatment period in TILS-025

Trial phase Phase 2a Open-label intranasal foralumab MSA study

Congress edition 7th 7th World Parkinson Congress hosting the late-breaking poster

Historical Context

5 past events · Latest: Apr 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 01	Preclinical cognition data	Positive	+6.8%	Preclinical intranasal anti-CD3 data showed improved cognition and reduced brain aging markers.
Feb 25	Biomarker clinical update	Positive	+4.5%	Biomarker data linked foralumab to reduced CSF inflammation and microglial activation in na-SPMS.
Jan 20	Peer-reviewed publication	Positive	-6.0%	Open-label na-SPMS study publication reported clinical stability, PET and biomarker improvements.
Jan 16	Registered direct closing	Positive	+15.9%	Closing of $8.8M oversubscribed direct offering with warrants, led by management participation.
Jan 16	Registered direct pricing	Positive	+15.9%	Pricing of up to $17.6M registered direct to fund Phase 2 na‑SPMS and MSA trials.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive neuroinflammation data and financing updates often coincided with positive price reactions, with one notable divergence on a strong clinical publication.

Recent Company History

Over recent months, Tiziana highlighted multiple advances for intranasal foralumab. On Jan 16, 2026, company-led offerings tied to funding Phase 2 na‑SPMS and MSA trials saw shares gain about 15.86%. A peer‑reviewed na‑SPMS publication on Jan 20, 2026 was followed by a -5.95% move. Subsequent biomarker (Feb 25, 2026) and preclinical aging data (Apr 1, 2026) drew positive reactions. Today’s MSA Phase 2a poster acceptance fits this ongoing neurodegenerative focus.

Key Terms

intranasal foralumab, anti-cd3, monoclonal antibody, multiple system atrophy, +4 more

8 terms

intranasal foralumab medical

"developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody"

Intranasal foralumab is an experimental antibody medication given as a spray or drops into the nose that aims to change how the immune system behaves rather than attack a virus directly. Investors care because results from trials, safety findings, and regulatory decisions determine whether this approach can become a marketed therapy, affecting a company’s future sales, development costs and competitive position — similar to betting on a new product that could reshape a company’s revenue stream.

anti-cd3 medical

"intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that a late-breaking poster"

An anti‑CD3 is an antibody drug that binds to the CD3 protein on T cells, the immune system’s frontline soldiers, to change how those cells behave. Think of it like attaching a remote control to specific immune cells to dial their activity up, down or redirect them; for investors, anti‑CD3 therapies signal a drug class with significant promise in autoimmune diseases, transplant protection and certain cancer strategies, but also carry clinical, regulatory and safety risks that strongly influence valuation and trial outcomes.

monoclonal antibody medical

"intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that a late-breaking poster"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

multiple system atrophy medical

"Phase 2a study of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted"

A progressive neurological disorder that damages multiple areas of the nervous system, causing problems with movement, balance and involuntary functions like blood pressure and bladder control; think of it as critical wiring in the body slowly failing. Investors care because the condition defines the size and urgency of the market for treatments, influences clinical trial difficulty and regulatory risk, and can lead to high per-patient pricing but also greater development uncertainty.

microglial activation medical

"Neuroinflammation and microglial activation are recognized as key drivers of disease progression."

Microglial activation is when the brain’s resident immune cells — microglia — switch from a resting, maintenance role into an alert, defensive state, similar to a neighborhood cleanup crew suddenly racing to douse a small fire. For investors, this matters because persistent or excessive activation is a hallmark of many neurological diseases, affects how drugs perform in trials, and can drive regulatory and market reactions to therapies aimed at calming or harnessing this response.

tsopet imaging medical

"changes in microglial activation measured by [F-18]PBR06 TSPO PET imaging and changes"

TSPO PET imaging uses a tiny radioactive tracer and a PET scanner to show where the translocator protein (TSPO) is concentrated in the body; TSPO tends to rise in areas where immune cells are active, especially in the brain. Investors care because it provides a noninvasive way to measure inflammation or disease activity and to track whether a drug is having an effect — like a thermometer for biological activity — which can affect clinical progress and company valuation.

mds-umsars medical

"Primary endpoints include changes in microglial activation ... and changes in MDS-UMSARS scores."

MDS-UMSARS is a clinician‑administered rating scale used in clinical trials to measure the severity and progression of multiple system atrophy, a progressive neurological disorder. Think of it like a detailed checklist doctors use to score a patient’s symptoms and daily functioning over time; changes in the score serve as measurable trial outcomes. Investors care because improvements or slowing of decline on this scale often determine drug trial success, regulatory decisions, and commercial prospects.

volumetric mri medical

"Secondary endpoints encompass regional brain atrophy on volumetric MRI, autonomic function"

Volumetric MRI is a type of magnetic resonance imaging that captures three-dimensional, measurable images of an organ or tissue so clinicians can calculate precise volumes rather than relying on flat slices. For investors, it matters because more accurate, repeatable measurements improve diagnosis, track treatment effects, and can serve as reliable clinical-trial endpoints or product differentiators, which in turn influence regulatory decisions, reimbursement and market value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the 7th World Parkinson Congress, taking place May 24-27, 2026, in Phoenix, Arizona.

The poster, titled “A Phase 2a Study of Intranasal Foralumab in Multiple System Atrophy,” will highlight the design and rationale of the ongoing TILS-025 trial (NCT06868628), the first clinical investigation of intranasal anti-CD3 therapy in MSA.

Multiple System Atrophy is a rapidly progressive neurodegenerative disorder characterized by autonomic dysfunction, parkinsonism, and cerebellar impairment, with no approved disease-modifying therapies. Neuroinflammation and microglial activation are recognized as key drivers of disease progression. Foralumab, delivered intranasally, has previously shown a reduction of neuroinflammation in clinical studies for multiple sclerosis and Alzheimer’s disease. The TILS-025 study evaluates its potential to attenuate microglial activation in MSA.

This Phase 2a, open-label trial is enrolling up to 10 subjects with clinically established or clinically probable MSA (per 2022 MDS criteria), ages 30–85, in collaboration with the Mass General Brigham MyTrial-MSA and Harvard Biomarkers Study 2.0 programs. Participants receive intranasal foralumab (50 μg per dose) for 6 months, with pre-treatment observational data collected where available. Primary endpoints include changes in microglial activation measured by [F-18]PBR06 TSPO PET imaging and changes in MDS-UMSARS scores. Secondary endpoints encompass regional brain atrophy on volumetric MRI, autonomic function, quality-of-life measures, and immune biomarkers in blood and CSF.

“We are thrilled that our Phase 2a study of intranasal foralumab in Multiple System Atrophy has been selected as a late-breaking poster at the 7th World Parkinson Congress,” said Ivor Elrifi, CEO of Tiziana Life Sciences. “This acceptance underscores the growing interest in foralumab’s novel intranasal approach to modulating neuroinflammation. MSA is a devastating disease with high unmet need, and we believe foralumab’s ability to target microglial activation could represent a meaningful step forward for patients. We look forward to sharing updates from this important trial with the global Parkinson’s and MSA community in Phoenix.”

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biologic candidate that has been shown to stimulate T regulatory cells when dosed intranasally. Currently, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2],[3]

About Tiziana Life Sciences

Tiziana is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Tiziana's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Tiziana's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Tiziana cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of Tiziana only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Tiziana will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
[3] https://www.neurology.org/doi/10.1212/NXI.0000000000200543

FAQ

What will Tiziana present about intranasal foralumab at the 7th World Parkinson Congress (TLSA)?

Tiziana will present a late-breaking poster on its Phase 2a TILS-025 trial of intranasal foralumab in MSA. According to the company, the poster covers trial design, endpoints, and rationale for targeting microglial activation in Multiple System Atrophy.

What are the primary endpoints of the TILS-025 Phase 2a study (TLSA) in MSA?

The primary endpoints are changes in microglial activation by [F-18]PBR06 TSPO PET imaging and MDS-UMSARS clinical scores. According to the company, these measure neuroinflammation and clinical progression over the six-month treatment period.

How many patients and what dosing does the TLSA TILS-025 study use for foralumab?

TILS-025 is an open-label trial enrolling up to 10 subjects with clinically established or probable MSA, ages 30–85. According to the company, participants receive intranasal foralumab at 50 μg per dose for six months.

Which secondary outcomes does Tiziana include in the TILS-025 MSA study (TLSA)?

Secondary outcomes include regional brain atrophy on volumetric MRI, autonomic function, quality-of-life measures, and immune biomarkers in blood and CSF. According to the company, these assess structural, functional, and immune effects alongside PET and clinical scores.

When and where will the late-breaking poster on TLSA's foralumab in MSA be presented?

The poster will be presented at the 7th World Parkinson Congress taking place May 24–27, 2026, in Phoenix, Arizona. According to the company, it was accepted as a late-breaking poster for that meeting.